These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 38730737)

  • 41. [Significance of neutrophil-to-lymphocyte ratio in atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma].
    Kaneko Y; Kaneshiro M; Watanabe H
    Nihon Shokakibyo Gakkai Zasshi; 2023; 120(10):837-844. PubMed ID: 37821373
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pathological complete response of hepatocellular carcinoma confirmed by conversion hepatectomy following atezolizumab plus bevacizumab therapy: a case report and literature review.
    Sato S; Aoki T; Matsumoto T; Shiraki T; Mori S; Iso Y; Nemoto T; Onishi T; Iijima M; Ishida K
    Clin J Gastroenterol; 2024 Apr; 17(2):292-299. PubMed ID: 38071671
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Association of Hepatobiliary Phase of Gadoxetic-Acid-Enhanced MRI Imaging with Immune Microenvironment and Response to Atezolizumab Plus Bevacizumab Treatment.
    Tamura Y; Ono A; Nakahara H; Hayes CN; Fujii Y; Zhang P; Yamauchi M; Uchikawa S; Teraoka Y; Uchida T; Fujino H; Nakahara T; Murakami E; Tsuge M; Serikawa M; Miki D; Kawaoka T; Okamoto W; Imamura M; Nakamura Y; Awai K; Kobayashi T; Ohdan H; Fujita M; Nakagawa H; Chayama K; Aikata H; Oka S
    Cancers (Basel); 2023 Aug; 15(17):. PubMed ID: 37686510
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Interleukin-6 Is a Circulating Prognostic Biomarker for Hepatocellular Carcinoma Patients Treated with Combined Immunotherapy.
    Myojin Y; Kodama T; Sakamori R; Maesaka K; Matsumae T; Sawai Y; Imai Y; Ohkawa K; Miyazaki M; Tanaka S; Mita E; Tawara S; Yakushijin T; Nozaki Y; Hagiwara H; Tahata Y; Yamada R; Hikita H; Tatsumi T; Takehara T
    Cancers (Basel); 2022 Feb; 14(4):. PubMed ID: 35205631
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Dynamic change of PD-L1 expression on circulating tumor cells in advanced solid tumor patients undergoing PD-1 blockade therapy.
    Yue C; Jiang Y; Li P; Wang Y; Xue J; Li N; Li D; Wang R; Dang Y; Hu Z; Yang Y; Xu J
    Oncoimmunology; 2018; 7(7):e1438111. PubMed ID: 29900038
    [No Abstract]   [Full Text] [Related]  

  • 46. Serum osteopontin predicts the response to atezolizumab plus bevacizumab in patients with hepatocellular carcinoma.
    Yamauchi R; Ito T; Yoshio S; Yamamoto T; Mizuno K; Ishigami M; Kawashima H; Yasuda S; Shimose S; Iwamoto H; Yamazoe T; Mori T; Kakazu E; Kawaguchi T; Toyoda H; Kanto T
    J Gastroenterol; 2023 Jun; 58(6):565-574. PubMed ID: 36991155
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Heterogeneous Expression of Programmed Death Receptor-ligand 1 on Circulating Tumor Cells in Patients With Lung Cancer.
    Koh Y; Yagi S; Akamatsu H; Kanai K; Hayata A; Tokudome N; Akamatsu K; Higuchi M; Kanbara H; Nakanishi M; Ueda H; Yamamoto N
    Clin Lung Cancer; 2019 Jul; 20(4):270-277.e1. PubMed ID: 31005568
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Initial therapeutic results of atezolizumab plus bevacizumab for unresectable advanced hepatocellular carcinoma and the importance of hepatic functional reserve.
    Tomonari T; Tani J; Sato Y; Tanaka H; Tanaka T; Taniguchi T; Asahiro M; Okamoto K; Sogabe M; Miyamoto H; Muguruma N; Masaki T; Takayama T
    Cancer Med; 2023 Feb; 12(3):2646-2657. PubMed ID: 35964253
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy and safety of immune checkpoint inhibitors for advanced non-small cell lung cancer with or without PD-L1 selection: A systematic review and network meta-analysis.
    Li Y; Liang X; Li H; Chen X
    Chin Med J (Engl); 2023 Sep; 136(18):2156-2165. PubMed ID: 37596898
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) in muscle invasive and metastatic bladder cancer patients.
    Anantharaman A; Friedlander T; Lu D; Krupa R; Premasekharan G; Hough J; Edwards M; Paz R; Lindquist K; Graf R; Jendrisak A; Louw J; Dugan L; Baird S; Wang Y; Dittamore R; Paris PL
    BMC Cancer; 2016 Sep; 16(1):744. PubMed ID: 27658492
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparison of Efficacy and Safety of Atezolizumab Plus Bevacizumab and Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Analysis.
    Niizeki T; Tokunaga T; Takami Y; Wada Y; Harada M; Shibata M; Nakao K; Sasaki R; Hirai F; Shakado S; Yoshizumi T; Itoh S; Yatsuhashi H; Bekki S; Ido A; Mawatari S; Honda K; Sugimoto R; Senju T; Takahashi H; Kuwashiro T; Maeshiro T; Nakamuta M; Aratake Y; Yamashita T; Otsuka Y; Matsumoto S; Sohda T; Shimose S; Murotani K; Tanaka Y
    Target Oncol; 2022 Nov; 17(6):643-653. PubMed ID: 36272060
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Concurrent Atezolizumab Plus Bevacizumab and High-Dose External Beam Radiotherapy for Highly Advanced Hepatocellular Carcinoma.
    Su CW; Teng W; Shen EY; Huang BS; Lin PT; Hou MM; Wu TH; Tsan DL; Hsieh CH; Wang CT; Chai PM; Lin CY; Lin SM; Lin CC
    Oncologist; 2024 Jul; 29(7):e922-e931. PubMed ID: 38530254
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical Correlations of Programmed Cell Death Ligand 1 Status in Liquid and Standard Biopsies in Breast Cancer.
    Jacot W; Mazel M; Mollevi C; Pouderoux S; D'Hondt V; Cayrefourcq L; Bourgier C; Boissiere-Michot F; Berrabah F; Lopez-Crapez E; Bidard FC; Viala M; Maudelonde T; Guiu S; Alix-Panabières C
    Clin Chem; 2020 Aug; 66(8):1093-1101. PubMed ID: 32712650
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Risk Factors for Early Onset of Proteinuria in Patients Receiving Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma.
    Ando Y; Kawaoka T; Kosaka M; Shirane Y; Johira Y; Miura R; Murakami S; Yano S; Amioka K; Naruto K; Kosaka Y; Uchikawa S; Kodama K; Fujino H; Nakahara T; Ono A; Murakami E; Yamauchi M; Okamoto W; Takahashi S; Imamura M; Aikata H
    Liver Cancer; 2023 Aug; 12(3):251-261. PubMed ID: 37601981
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Evaluation of PD-L1 expression on circulating tumor cells (CTCs) in patients with advanced urothelial carcinoma (UC).
    Bergmann S; Coym A; Ott L; Soave A; Rink M; Janning M; Stoupiec M; Coith C; Peine S; von Amsberg G; Pantel K; Riethdorf S
    Oncoimmunology; 2020; 9(1):1738798. PubMed ID: 32391189
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prognosis value of circulating tumor cell PD‑L1 and baseline characteristics in patients with NSCLC treated with immune checkpoint inhibitors plus platinum‑containing drugs.
    Su X; Zhou C; Chen S; Ma Q; Xiao H; Chen Q; Zou H
    Oncol Lett; 2024 Mar; 27(3):131. PubMed ID: 38362233
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Isatuximab plus atezolizumab in patients with advanced solid tumors: results from a phase I/II, open-label, multicenter study.
    Simonelli M; Garralda E; Eskens F; Gil-Martin M; Yen CJ; Obermannova R; Chao Y; Lonardi S; Melichar B; Moreno V; Yu ML; Bongiovanni A; Calvo E; Rottey S; Machiels JP; Gonzalez-Martin A; Paz-Ares L; Chang CL; Mason W; Lin CC; Reardon DA; Vieito M; Santoro A; Meng R; Abbadessa G; Menas F; Lee H; Liu Q; Combeau C; Ternes N; Ziti-Ljajic S; Massard C
    ESMO Open; 2022 Oct; 7(5):100562. PubMed ID: 35987165
    [TBL] [Abstract][Full Text] [Related]  

  • 58. PD-L1 Expression in Circulating Tumor Cells as a Promising Prognostic Biomarker in Advanced Non-small-cell Lung Cancer Treated with Immune Checkpoint Inhibitors.
    Dall'Olio FG; Gelsomino F; Conci N; Marcolin L; De Giglio A; Grilli G; Sperandi F; Fontana F; Terracciano M; Fragomeno B; Tober N; Manferrari G; Brocchi S; Golfieri R; Fiorentino M; Ardizzoni A
    Clin Lung Cancer; 2021 Sep; 22(5):423-431. PubMed ID: 33849808
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Association of High Levels of Antidrug Antibodies Against Atezolizumab With Clinical Outcomes and T-Cell Responses in Patients With Hepatocellular Carcinoma.
    Kim C; Yang H; Kim I; Kang B; Kim H; Kim H; Lee WS; Jung S; Lim HY; Cheon J; Chon HJ
    JAMA Oncol; 2022 Dec; 8(12):1825-1829. PubMed ID: 36264560
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor Nivolumab.
    Nicolazzo C; Raimondi C; Mancini M; Caponnetto S; Gradilone A; Gandini O; Mastromartino M; Del Bene G; Prete A; Longo F; Cortesi E; Gazzaniga P
    Sci Rep; 2016 Aug; 6():31726. PubMed ID: 27553175
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.